nothing has to do with bristol meyers. be sure you're dealing with a momentarily damaged stock rather than one that's going down, down, down. how do you tell the difference in the fundamentals haven't changed, the stock probably hasn't fallen from grace, pull back largely for mechanical reasons, profit-taking or panic in the market and more than ever thanks to the fact that stocks with traded like commodities causing huge selloffs that make sense or anything and double or triple related etfs more powerful than the stocks themselves, you see the stocks of good companies pull back from their highs for nothing that happened to do at the company, nothing to do with the company or the strength of the underlying businesses. those are the buys. >> buy, buy, buy. >> but if the fundamental picture changes, whatever made the strong attractive goes away then that stock is no longer a candidate. >> sell, sell sell? the story has to be intact or this method will let you down. while this isn't a hard and fast rule i like stocks pulled b

. >> for bristol meyer, you're voy and deneffo upset headwinds and for even pfizer new cancer treatments were strong. >> the i brands -- ibrance number came in at $38 million and that was only in -- that was in the very early stages. >> analysts say pharmaceutical companies are set to reap the benefits of cycle of drug introductions with a number of specialty treatments in the pipeline. bertha coombs "nightly business repo new york. >> but will the new specialty treatments she just mentioned be affordable for everyone? personalized treatment for cancer and cys can cost tens and hundreds of thousands of dollars a year and in some cases they prolong life by just a few months. dr. peter balk is director of the kettering sloan center for outcome and joins us for insight. doctor welcome. good to have you with us. in a phrase or two, why do drugs cost so much in the united states and why do the prices keep rising as rapidly as they do apart from the break-through personalized drugs that we're seeing more and more of? >> well tyler, thank you for having me. i think what we see is very rapid ris

buy bristol meyers instead of that and you'll be fine. we'll go back to calling it a facebook.was a mistake, but i kind of liked face back. don't you like that? that would be the mock facebook. let's go to frank in california. frank. >> caller: yeah, jim how you doing? >> pretty good how about you? >> caller: i'm doing fantastic. here's my stocks. teva trgo cfe, ccl, and kr. >> okay that's good. let's see. carnival as we just profiled that the other day. let's call that travel and leisure. kroger will break out. perrigo. you have that we have to make changes. let's call this a knock off and not sell it t. you know what we're going to do? buy a kinder morgan. let's go to jennifer in ohio. >> caller: hello. >> jennifer. >> caller: my stocks are apple, ford gilliad, skyworks and the last one i'd like to know if i should sell before reports next week and the suggestion, for replacement and it is slumber j. we're all over these. let's see. gilliad, one of the four horseman. skyworks terrific technology. that's david alders the inside of a cell phone. ford that's more fields doing a

seeing some good news for merck and bris yol bristol meyer. the flip side of that these car t technologies. this basket of stocks we talked about as being very very volatile. an area of immu know oncology we've talked about, juno and kite, down quite a bit after rising in anticipation of seeing some data in solid tumors at this meeting. they have been very successful so far in blood cancers like leukemia. off of that, there is a new name that just went public last week. stock up 7% because of those same data. essentially the same target. they have a cancer vaccine. some an libss saying the data presented was good for aduro. >> they're filing for another application for nonsmall cell lung and analysts are saying that's a much bigger patient population. could that move the needle for a company of merck's size? >> i think it absolutely would. lung cancer is one of the highest on medical needs. melanoma was. the problem is how do you differentiate between the bristol-myers brookdrug and the bristol drug. it's going to be very interesting to see ho

bristol meyers also seeing its biggest gain in six weeks on an encouraging cancer drug study.ck also defying the declines overall. and matel. posting a smaller than expected loss last quarter. sales declined at two important units. barbie and fisher price have slowed down. it's not as bad as anticipated. that was good for a 5.8% advance. the other gainers in the market, as you might expect teva is looking to acquire mylan. this is not new news. but new reporting shows that discussions are taking place. andy: giving us those positive -- alix: giving us those positive moments. it's a rehash here. we're looking at stocks, looking at the worst day since march 25. you have the vix also jumping the most in three weeks. so more volatility coming. as we see stocks falling off. the s&p sectors finishing in the red. all dow numbers finishing in the red. really a global selloff end to out the week. joining me to help break it down is a chief economist. u.b.s. financial strategist and bloomberg chief economist. lots of factors here behind the selloff. let's go through them. we have greek

shares of merck, pfizer and bristol meyers all moving higher in the free market. >> numbers from ford disappoint. north america the bright spot. the company continues to lose in south america and if europe. we will interview the cfo bob shanks a little later on. apple poised to open up 33% if profits. more than 61 million iphones were sold. revenue in china grew 71% from a year ago him apple boosting the capital return program. tim cook on last night's conference call. take a listen. >> we are in the very fortunate position of generating more cash than we need to run our business an keep making these important investments. so today, we're announcing another significant update to our capital return program, expanding its size to $200 billion through march of 2017 to reflect our strong confidence in what lies ahead for apple. >> of course jim the record cash now at $194 billion. pointing out they can combine gm and ford and tesla and still have some left in the bank. >> my answer is why the heck would they want to do that? okay. this is one of those quarters where tim cook really had to